{
  "id": 4736124,
  "title": "Synopsys executive chair Aart de Geus sells $11.1m in stock",
  "url": "https://urgent.news/2026/08/31/synopsys-executive-chair-aart-de-geus-sells-11-1m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T23:01:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/synopsys-executive-chair-aart-de-geus-sells-111m-in-stock-93CH-4883363"
  },
  "original_language": "en",
  "account": "Synopsys executive chair Aart de Geus sold shares worth $11.1 million on August 28, 2026, exercising his right under a Rule 10b5-1 trading plan. The sale took place at prices between $440.985 and $461.850, averaging a sale price of $445.5502. Concurrently, de Geus purchased 25,000 shares using non-qualified stock options, paying $3.397 million. Post-transaction, he owns 120,421 shares directly, 308,791 indirectly through family trusts, and 14,500 indirectly through partnerships, along with 49,641 stock options. Synopsys boasts gross profit margins of 83%, and is viewed as undervalued by InvestingPro’s Fair Value analysis. The company reported Q3 2026 results beating estimates, with non-GAAP earnings of $3.91 per share and revenue of $2.48 billion, surpassing Wall Street's forecasts. Boosted by this success, Synopsys raised its full-year guidance. Benchmark and Baird analysts have raised their ratings for Synopsys, citing positive growth expectations.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}